Advertisement
MIST vs RCKT
Which Stock Would AI Choose? Milestone Pharmaceuticals (MIST) vs. Rocket Pharmaceuticals (RCKT) Stock Comparison
Key Takeaways
- MIST is now a commercial-stage biopharmaceutical company ramping sales of CARDAMYST, its recently approved nasal spray, while RCKT is a gene-therapy developer with a newly approved first product but limited near-term revenue.
- Recent momentum and market positioning favor MIST, which has expanding insurance coverage, rising prescription counts, and a Strong Buy analyst consensus.
- RCKT carries longer, higher-risk timelines, with its pivotal Danon disease trial readout not expected until mid-2028.
- Tickeron AI Verdict: MIST is the favored ticker of the two, based on relative trend consistency, nearer-term catalysts, and observable revenue momentum.
- Get more detail on the latest developments: MIST Major News, MIST Today's Price Move, RCKT Major News, and RCKT Today's Price Move.
- Discover curated strategies powered by quantitative signals on the Trending AI Robots page.
Introduction
Investors weighing small-cap biotechnology names often face a trade-off between near-term commercial execution and longer-term pipeline potential. This stock comparison examines MIST (Milestone Pharmaceuticals) and RCKT (Rocket Pharmaceuticals), two clinical-to-commercial healthcare companies operating in different corners of cardiovascular medicine. Both have crossed meaningful regulatory milestones in recent months, yet their relative performance and market positioning have diverged. Growth-oriented traders and biotech investors evaluating momentum, catalysts, and risk profiles may find this head-to-head comparison useful for understanding how the two names currently stack up.
MIST Overview and Recent Performance
MIST is a biopharmaceutical company focused on cardiovascular medicines, anchored by CARDAMYST (etripamil), a nasal spray approved to treat paroxysmal supraventricular tachycardia (PSVT), a condition marked by sudden episodes of rapid heartbeat. The commercial launch began in early 2026, and recent market activity has been shaped by steady uptake: prescription volumes grew month over month, unique prescribers expanded, and insurance coverage widened after a major pharmacy benefit manager (PBM) added the drug to national formularies, with management later reporting coverage above roughly 50% of commercially insured lives. In recent weeks, the company also presented new clinical data and announced its first regulatory approval outside the United States, in China. Despite early-stage revenue that remains modest relative to expenses, the launch trajectory, a growing cash runway, and a Strong Buy consensus from sell-side analysts have underpinned sentiment.
RCKT Overview and Recent Performance
RCKT is a fully integrated gene-therapy company developing genetic medicines for rare cardiovascular, hematologic, and immunologic disorders. Its lead program, RP-A501, targets Danon disease, a rare inherited heart condition, in a pivotal Phase 2 trial. The company achieved a significant milestone with the accelerated approval of Kresladi for severe leukocyte adhesion deficiency type I (LAD-I), a rare pediatric immune disorder, and subsequently monetized its Priority Review Voucher (PRV) for $180 million. Recent weeks brought a strengthened balance sheet through a credit facility of up to $150 million, extending its operating runway. However, the stock has declined notably since the Kresladi approval, and its pivotal Danon disease readout remains several years away, leaving relative performance driven more by financing and regulatory execution than by recurring revenue.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of automated trading strategies from a broader universe of hundreds of AI trading bots that monitor thousands of tickers. Because market conditions shift constantly, only the bots best suited to the current environment earn a place in this section. The available bots vary widely by trading style, strategy, timeframe, performance statistics, and the sets of tickers they trade, so traders can compare approaches rather than rely on a single signal. Exploring this curated list can help investors evaluate how quantitative, rules-based systems are positioning across names like those in this comparison. Visit Trending AI Robots to review the latest selections.
Head-to-Head Comparison
The two companies differ sharply in business model and risk profile. MIST has shifted into a commercial launch phase, generating early product revenue and building payer access for an approved cardiovascular therapy, which gives it nearer-term, measurable catalysts. RCKT, by contrast, operates on a longer horizon: its first approved therapy targets an ultra-rare pediatric disease with limited near-term sales, while its core value rests on a pivotal gene-therapy trial that will not report topline data until mid-2028. On stability, MIST's expanding coverage and rising prescriptions offer more visible operating momentum, whereas RCKT's share price has been pressured since its approval, reflecting the binary nature of its pipeline. Both names carry sector-wide risks tied to regulatory review, reimbursement, and clinical execution, but the trade-off is essentially one of demonstrated launch traction versus long-dated, high-upside gene-therapy development.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst proximity, stability, and relative positioning, Tickeron's AI would currently lean toward MIST over RCKT. MIST's combination of a commercialized product, expanding formulary coverage, rising prescription counts, and a broadly favorable analyst consensus presents a more continuous, nearer-term fundamental backdrop. RCKT's long-dated pivotal readout and post-approval share-price weakness introduce greater timing uncertainty, even though its strengthened cash position reduces near-term funding risk. This assessment is probabilistic rather than definitive and reflects the comparative momentum and market positioning of the two tickers at this point in time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MIST is a Hold and RCKT is a Hold.
MIST in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 23, 2026
MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 37 cases where MIST's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MIST's RSI Indicator exited the oversold zone, 24 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for MIST just turned positive on October 27, 2026. Looking at past instances where MIST's MACD turned positive, the stock continued to rise in 34 of 43 cases over the following month. The odds of a continued upward trend are 79%.
Following a +7.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIST as a result. In 67 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MIST entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.213) is normal, around the industry mean (3.498). P/E Ratio (-1.174) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RCKT in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 16, 2026
RCKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 39 cases where RCKT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RCKT's RSI Indicator exited the oversold zone, 31 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for RCKT just turned positive on October 20, 2026. Looking at past instances where RCKT's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
Following a +5.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in 201 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 58 cases where RCKT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCKT as a result. In 71 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for RCKT entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.710) is normal, around the industry mean (3.498). P/E Ratio (-14.906) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. RCKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MIST | RCKT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 22 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 73 Overvalued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 92 | |
PRICE GROWTH RATING 1..100 | 85 | 73 | |
P/E GROWTH RATING 1..100 | 13 | 15 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RCKT's Valuation (11) in the Biotechnology industry is somewhat better than the same rating for MIST (73) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew somewhat faster than MIST’s over the last 12 months.
RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to MIST’s over the last 12 months.
RCKT's SMR Rating (92) in the Biotechnology industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to MIST’s over the last 12 months.
RCKT's Price Growth Rating (73) in the Biotechnology industry is in the same range as MIST (85) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to MIST’s over the last 12 months.
MIST's P/E Growth Rating (13) in the Pharmaceuticals Major industry is in the same range as RCKT (15) in the Biotechnology industry. This means that MIST’s stock grew similarly to RCKT’s over the last 12 months.
| MIST | RCKT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 79% |
| Stochastic ODDS (%) | 1 day ago 86% | 1 day ago 86% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 89% |
| MACD ODDS (%) | 1 day ago 79% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 79% |
| Advances ODDS (%) | 9 days ago 84% | 9 days ago 80% |
| Declines ODDS (%) | 3 days ago 85% | 7 days ago 87% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MIST’s FA Score shows that 1 FA rating(s) are green while RCKT’s FA Score has 2 green FA rating(s).
- MIST’s FA Score: 1 green, 4 red.
- RCKT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MIST’s TA Score shows that 5 TA indicator(s) are bullish while RCKT’s TA Score has 4 bullish TA indicator(s).
- MIST’s TA Score: 5 bullish, 3 bearish.
- RCKT’s TA Score: 4 bullish, 4 bearish.
Price Growth
MIST (@Biotechnology) experienced а -14.28% price change this week, while RCKT (@Biotechnology) price change was -4.98% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
MIST is expected to report earnings on Nov 13, 2026.
RCKT is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MIST and
Correlation & Price change
A.I.dvisor indicates that over the last year, MIST has been loosely correlated with RCUS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MIST jumps, then RCUS could also see price increases.
| Ticker / NAME | Correlation To MIST | 1D Price Change % | ||
|---|---|---|---|---|
| MIST | 100% | N/A | ||
| RCUS - MIST | 45% Loosely correlated | +0.70% | ||
| TSHA - MIST | 41% Loosely correlated | +0.12% | ||
| RCKT - MIST | 41% Loosely correlated | +1.22% | ||
| DYN - MIST | 40% Loosely correlated | +0.39% | ||
| NAMS - MIST | 40% Loosely correlated | +8.03% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QGRO | 115.27 | 1.96 | +1.73% |
| American Century U.S. Quality Growth ETF (QGRO) | |||
| BBHM | 12.21 | 0.17 | +1.45% |
| BBH Select Mid Cap ETF (BBHM) | |||
| PGP | 8.37 | 0.02 | +0.24% |
| PIMCO Global StockPLUS & Income Fund | |||
| LFAW | 167.02 | N/A | N/A |
| LifeX 2060 Longevity Income ETF (LFAW) | |||
| HIBS | 19.80 | -2.03 | -9.30% |
| Direxion Daily S&P 500 High Beta Bear 3X ETF (HIBS) | |||